Literature DB >> 345280

Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives.

K Umezawa, A Shirai, T Matsushima, T Sugimura.   

Abstract

Norharman enhanced the known mutagenicity of 2-acetylaminofluorene derivatives in the Salmonella test system. The mutagenicities of 2-acetylaminofluorene, 2-aminofluorene, and N-hydroxy-2-acetylaminofluorene were enhanced by norharman only when rat liver microsomal enzymes were added, whereas the mutagenicity of N-acetoxy-2-acetylaminofluorene was increased in the absence of microsomal enzymes. Harman also increased mutagenesis, althouth less so than norharman.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 345280      PMCID： PMC411371          DOI： 10.1073/pnas.75.2.928

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  10 in total

1.  The N- and ringhydroxylation of 2-acetylaminofluorene during carcinogenesis in the rat.

Authors:  J A MILLER; J W CRAMER; E C MILLER
Journal:  Cancer Res       Date:  1960-07       Impact factor: 12.701

2.  N-Hydroxylation: A new metabolic reaction observed in the rat with the carcinogen 2-acetylaminofluorene.

Authors:  J W CRAMER; J A MILLER; E C MILLER
Journal:  J Biol Chem       Date:  1960-03       Impact factor: 5.157

Review 3.  Carcinogenesis by chemicals: an overview--G. H. A. Clowes memorial lecture.

Authors:  J A Miller
Journal:  Cancer Res       Date:  1970-03       Impact factor: 12.701

4.  Mutations and decreases in density of transforming DNA produced by derivatives of the carcinogens 2-acetyl-aminofluorene and N-methyl-4-aminoazobenzene.

Authors:  V M Maher; E C Miller; J A Miller; W Szybalski
Journal:  Mol Pharmacol       Date:  1968-09       Impact factor: 4.436

5.  On the sulfate ester of N-hydroxy-N-2-fluorenylacetamide as a key ultimate hepatocarcinogen in the rat.

Authors:  J H Weisburger; R S Yamamoto; G M Williams; P H Grantham; T Matsushima; E K Weisburger
Journal:  Cancer Res       Date:  1972-03       Impact factor: 12.701

6.  Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test.

Authors:  B N Ames; J Mccann; E Yamasaki
Journal:  Mutat Res       Date:  1975-12       Impact factor: 2.433

7.  Interactions of norharman and harman with DNA.

Authors:  K Hayashi; M Nagao; T Sugimura
Journal:  Nucleic Acids Res       Date:  1977-11       Impact factor: 16.971

8.  Daunorubicin and adriamycin facilitate actinomycin D binding to poly(dA-dT)-poly(dA-dT).

Authors:  T R Krugh; M A Young
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

9.  Carcinogens as frameshift mutagens: metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens.

Authors:  B N Ames; E G Gurney; J A Miller; H Bartsch
Journal:  Proc Natl Acad Sci U S A       Date:  1972-11       Impact factor: 11.205

10.  Reactivity in vivo of the carcinogen N-hydroxy-2-acetylaminofluorene: increase by sulfate ion.

Authors:  J R DeBaun; J Y Smith; E C Miller; J A Miller
Journal:  Science       Date:  1970-01-09       Impact factor: 47.728
  10 in total
  4 in total

1.  Monoclonal antibody to 2-amino-3-methylimidazo(4,5-f)quinoline, a dietary carcinogen.

Authors:  H Yanagisawa; T Tachikawa; S Shin; O Wada
Journal:  Appl Biochem Biotechnol       Date:  1990-01       Impact factor: 2.926

2.  Effects of harman and norharman on the metabolism and genotoxicity of 2-acetylaminofluorene in cultured rat hepatocytes.

Authors:  J A Holme; E Søderlund; T Aune
Journal:  Cell Biol Toxicol       Date:  1985-06       Impact factor: 6.691

3.  Tissue damage and nutritional factors in experimental respiratory tract (Co-)carcinogenesis.

Authors:  P G Reuzel; V J Feron; B J Spit; R B Beems; R Kroes
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

4.  Enhancing effects of harman and norharman on induction of preneoplastic and neoplastic kidney lesions in rats initiated with N-ethyl-N-hydroxyethylnitrosamine.

Authors:  A Hagiwara; M Sano; E Asakawa; H Tanaka; R Hasegawa; N Ito
Journal:  Jpn J Cancer Res       Date:  1992-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.